# Article information:

Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension | NEJM
[https://www.nejm.org/doi/10.1056/NEJMoa2213169?url\_ver=Z39.88-2003=ori%3Arid%3Acrossref.org=cr\_pub++0pubmed](https://www.nejm.org/doi/10.1056/NEJMoa2213169?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed)

# Article summary:

1. Baxdrostat is a potential treatment for treatment-resistant hypertension.

2. In preclinical and phase 1 studies, baxdrostat had high selectivity for aldosterone synthase inhibition.

3. In a phase 2 trial, baxdrostat at various doses reduced systolic blood pressure in patients with treatment-resistant hypertension.

# Article rating:

Appears strongly imbalanced: The article is written in a biased or one-sided way, and the information it provides is not trustworthy enough to be considered a reliable source. You should consult other sources to find reliable information on the presented issues.

# Article analysis:

由于本文仅提供了文章的摘要，无法进行详细的批判性分析。需要更多信息才能确定是否存在潜在偏见、片面报道、无根据的主张、缺失的考虑点、所提出主张的缺失证据、未探索的反驳、宣传内容，偏袒，是否注意到可能的风险，没有平等地呈现双方等问题。建议阅读完整文章后再进行分析。

# Topics for further research:

* Potential biases in the article
* One-sided reporting
* Unsupported claims
* Missing considerations
* Lack of evidence for presented claims
* Unexplored counterarguments or biases

# Report location:

<https://www.fullpicture.app/item/b07b6116cadb4b876c611efc11fe91f5>